UPDATE 1-Merck's Keytruda wins FDA approval as combination therapy for kidney cancer
April 22, 2019 at 07:37 AM EDT
The U.S. Food and Drug Administration has approved Merck & Co Inc's cancer therapy, Keytruda, as part of a combination therapy for previously untreated patients with the most common type of kidney cancer, the company said on Monday.
